Chappey C - Search Results

1

Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.

Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, Petropoulos CJ. Parkin N, et al. Among authors: chappey c. J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):128-36. doi: 10.1097/00126334-200210010-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12394790

2

Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Parkin NT, et al. Among authors: chappey c. Antimicrob Agents Chemother. 2004 Feb;48(2):437-43. doi: 10.1128/AAC.48.2.437-443.2004. Antimicrob Agents Chemother. 2004. PMID: 14742192 Free PMC article.

3

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.

Parkin NT, Chappey C, Petropoulos CJ. Parkin NT, et al. Among authors: chappey c. AIDS. 2003 May 2;17(7):955-61. doi: 10.1097/00002030-200305020-00003. AIDS. 2003. PMID: 12700444

4

Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Whitcomb JM, et al. Among authors: chappey c. J Infect Dis. 2003 Oct 1;188(7):992-1000. doi: 10.1086/378281. Epub 2003 Sep 16. J Infect Dis. 2003. PMID: 14513419

5

The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.

Parkin NT, Gupta S, Chappey C, Petropoulos CJ. Parkin NT, et al. Among authors: chappey c. Antimicrob Agents Chemother. 2006 Jan;50(1):351-4. doi: 10.1128/AAC.50.1.351-354.2006. Antimicrob Agents Chemother. 2006. PMID: 16377709 Free PMC article.

6

Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals.

Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, Petropoulos CJ, Wrin T. Schweighardt B, et al. Among authors: chappey c. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):1-11. doi: 10.1097/QAI.0b013e318074eb5a. J Acquir Immune Defic Syndr. 2007. PMID: 17514017

7

Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.

Whitehurst N, Chappey C, Petropoulos C, Parkin N, Gamarnik A. Whitehurst N, et al. Among authors: chappey c. AIDS Res Hum Retroviruses. 2003 Sep;19(9):779-84. doi: 10.1089/088922203769232575. AIDS Res Hum Retroviruses. 2003. PMID: 14585208

8

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.

Ross L, Parkin N, Chappey C, Fisher R, Clair MS, Bates M, Tisdale M, Lanier ER. Ross L, et al. Among authors: chappey c. AIDS. 2004 Aug 20;18(12):1691-6. doi: 10.1097/01.aids.0000131355.44834.e4. AIDS. 2004. PMID: 15280780

9

Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.

Ross LL, Parkin N, Gerondelis P, Chappey C, Underwood MR, St Clair MH, Lanier ER. Ross LL, et al. Among authors: chappey c. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):567-70. doi: 10.1097/01.qai.0000243123.90400.62. J Acquir Immune Defic Syndr. 2006. PMID: 17075395

10

Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.

McColl DJ, Chappey C, Parkin NT, Miller MD. McColl DJ, et al. Among authors: chappey c. Antivir Ther. 2008;13(2):189-97. Antivir Ther. 2008. PMID: 18505170

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters